Doses - DACTINOMYCIN
Also see the section on antineoplastic protocols found in the appendix.
a) 0.7 mg/m2 IV every 7 days (Jacobs, Lumsden et al. 1992)
Monitoring Parameters - 1) Efficacy; 2) Toxicity: including CBC with differential and platelets;hepatic function tests; check inside patient's mouth for ulceration
Client Information - Inform clients of the potential toxicities and risks associated with this therapy and to report immediately any signs associated with serious toxicity (e.g., bloody vomiting or diarrhea, abnormal bleeding, bruising, urination, depression, infection, shortness of breath, etc.).
Dosage Forms/Preparations/FDA Approval Status/Withholding Times - Veterinary-Approved Products: None
a) 0.7 mg/m2 IV every 7 days (Jacobs, Lumsden et al. 1992)
Monitoring Parameters - 1) Efficacy; 2) Toxicity: including CBC with differential and platelets;hepatic function tests; check inside patient's mouth for ulceration
Client Information - Inform clients of the potential toxicities and risks associated with this therapy and to report immediately any signs associated with serious toxicity (e.g., bloody vomiting or diarrhea, abnormal bleeding, bruising, urination, depression, infection, shortness of breath, etc.).
Dosage Forms/Preparations/FDA Approval Status/Withholding Times - Veterinary-Approved Products: None